Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea

Fineline Cube Apr 9, 2026
Company Deals

Grand Pharma Partners with HKU on Anti‑Infective Drug Discovery – Exclusive License Deal Targets Novel Antibacterial Therapies

Fineline Cube Apr 9, 2026
Company Deals

Wuhan Ammunition Life-tech Files Hong Kong IPO Prospectus, Pioneering Methylation-Based Early Cancer Detection with Liver and Urothelial Cancer Tests

Fineline Cube Apr 8, 2026
Company Deals

Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline

Fineline Cube Apr 8, 2026
Company Deals

Biogen Licenses Alloy Therapeutics’ AntiClastic ASO Platform to Advance Next-Generation Antisense Therapy Research

Fineline Cube Apr 8, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Fineline Cube Apr 9, 2026
Company Drug

Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia

Fineline Cube Apr 9, 2026
Company Deals

Summit Therapeutics and Pfizer Collaborate on Ivonescimab-ADC Combo for Solid Tumors

Fineline Cube Feb 25, 2025

Summit Therapeutics Inc. (NASDAQ: SMMT), the U.S. partner of China-based Akeso Inc. (HKG: 9926) for...

Company

Dizal Pharma’s 2024 Revenues Surge 295% to RMB360M, Loss Narrows by RMB251M

Fineline Cube Feb 25, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) released its 2024 financial preview, showing annual revenues...

Company Drug

Bristol-Myers Squibb’s Opdivo-Yervoy Combo Nears FDA Approval for MSI-H Colorectal Cancer

Fineline Cube Feb 25, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) announced that the U.S. FDA has accepted its filing for...

Company Drug

CanSino Biologics Receives NMPA Approval for DTcP Hib MCV4 Combined Vaccine

Fineline Cube Feb 25, 2025

China-based vaccine specialist CanSino Biologics Inc. (HKG: 6185) announced that its absorbed diphtheria, tetanus, acellular...

Company Deals

MGI Tech Partners with Oncoclínicas&Co to Advance Precision Medicine in Brazil

Fineline Cube Feb 25, 2025

China-based gene sequencing specialist MGI Tech Co., Ltd (SHA: 688114) has partnered with OC Medicina...

Company Drug

Boehringer Ingelheim’s Nerandomilast Receives NMPA Review for IPF Treatment

Fineline Cube Feb 25, 2025

Boehringer Ingelheim announced that its investigational drug nerandomilast has been accepted for review by the...

Company Drug

QYuns Therapeutics’ QX002N Meets Primary Endpoint in AS Phase III Study

Fineline Cube Feb 25, 2025

China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) announced that its Phase III study of...

Company Drug

Takeda’s Takhzyro Receives EMA Approval for New Administration Form in HAE Patients

Fineline Cube Feb 25, 2025

Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) announced that the European Medicines Agency (EMA) has approved...

Policy / Regulatory

National Allied Procurement Office Allows VBP Winners to Adjust MAH and Manufacturing Details

Fineline Cube Feb 24, 2025

The National Allied Procurement Office has issued a notification clarifying rules for China’s Volume-Based Procurement...

Company

Ipsen Posts 8.7% Revenue Growth in 2024, Driven by Rare Diseases and Oncology

Fineline Cube Feb 24, 2025

French biopharma firm Ipsen (EPA: IPN, OTCMKTS: IPSEY) reported an 8.7% year-on-year (YOY) increase in...

Company Drug

Meyer FSMP Hong Kong Secures NMPA Approval for First FSMP in Greater China

Fineline Cube Feb 24, 2025

Hong Kong-based Meyer FSMP Hong Kong Limited, an oncology-focused foods for special medical purpose (FSMP)...

Company Deals Drug

Pfizer Halts Global Development of Hemophilia B Gene Therapy Beqvez Amid Limited Demand

Fineline Cube Feb 24, 2025

Pfizer Inc. (NYSE: PFE) has terminated the development and commercialization of Beqvez (fidanacogene elaparvovec), its...

Company Deals

Jointown Pharmaceutical Partners with Shandong DYNE to Boost Pediatric Drug Distribution

Fineline Cube Feb 24, 2025

Jointown Pharmaceutical Group Co., Ltd (SHA: 600998), China’s largest private pharmaceutical distributor, has partnered with...

Company Drug

CSPC Pharmaceutical Initiates Phase III Trial for Ammuxetine in Depression Treatment

Fineline Cube Feb 24, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced the start of a Phase III clinical...

Company Medical Device

Subtle Medical Integrates DeepSeek with FDA-Approved SupMR AI Platform

Fineline Cube Feb 24, 2025

Shanghai-based Subtle Medical Inc., an AI-powered medical imaging firm operating in the U.S. and China,...

Company Deals

AWS Collaborates with MSK to Accelerate Oncology Research via AI and Cloud Tech

Fineline Cube Feb 24, 2025

Amazon Web Services (AWS) announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK),...

Company Deals

Cholesgen Raises Over RMB100M in Series A to Advance Metabolic Disease Pipelines

Fineline Cube Feb 24, 2025

China-based glycolipid metabolism specialist Cholesgen (Shanghai) Co. Ltd. has reportedly raised over RMB100 million ($13.8...

Company Drug

Innorna’s IN013 Receives FDA Rare Pediatric Designation for Wilson’s Disease Treatment

Fineline Cube Feb 24, 2025

Shenzhen-based Innorna Co., Ltd, a platform company leveraging mRNA and lipid nanoparticle (LNP) delivery technologies,...

Company Deals

Amoytop Biotech to Acquire Skyline Therapeutics’ Gene Therapy Assets for $15M Plus Milestones

Fineline Cube Feb 24, 2025

Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has announced plans to acquire partial assets of...

Company

Novo Nordisk’s Emerging Business Division VP Eve Jiang Departs for External Opportunities

Fineline Cube Feb 24, 2025

Jiang Yiwei (Eve Jiang), corporate vice president (CVP) of Novo Nordisk’s (NYSE: NVO) Emerging Business...

Posts pagination

1 … 189 190 191 … 648

Recent updates

  • Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China
  • Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia
  • Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies
  • GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer
  • Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Company Drug

Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia

Company Drug

Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies

Company Drug

GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.